Abstract
To improve the oral absorption of meropenem (MEPM), we synthesized and evaluated a series of its double-promoiety prodrugs, in which lipophilic promoieties were introduced into carboxyl and pyrrolidinyl groups. Among these prodrugs, pivaloyloxymethyl (1R,5S,6S)-2-[(3S,5S)-5-(N,N-dimethylcarbamoyl)-1-(isobutyryloxymethyloxycarbonyl)pyrrolidin-3-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylate (4) and 1-ethylpropyloxycarbonyloxymethyl (1R,5S,6S)-2-[(3S,5S)-5-(N,N-dimethylcarbamoyl)-1-(isobutyryloxymethyloxycarbonyl)pyrrolidin-3-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylate (8) were chosen for further evaluation. Compounds 4 and 8 were well absorbed after oral administration to rats and beagles (bioavailability 18.2–38.4%), and expected to show potent therapeutic efficacy in patients infected with various pathogens, such as penicillin-resistant S. pneumoniae and β-lactamase-negative ampicillin-resistant H. influenzae.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Nicolau, D. P. Carbapenems: a potent class of antibiotics. Expert Opin. Pharmacother. 9, 23–37 (2008).
Bassetti, M., Nicolini, L., Esposito, S., Righi, E. & Viscoli, C. Current status of newer carbapenems. Curr. Med. Chem. 16, 564–575 (2009).
Neu, H. C. & Labthavikul, P. Comparative in vitro activity of N-formimidoyl thienamycin agent Gram-Positive and Gram-Negative aerobic and anaerobic species and its β-lactamase stability. Antimicrob. Agents Chemother. 21, 180–187 (1982).
Neu, H. C., Chin, N., Saha, G. & Labthavikul, P. In vitro activity against aerobic and anaerobic Gram-Positive and Gram-Negative Bacteria and β-lactamase stability of RS-533, a novel carbapenem. Antimicrob. Agents Chemother. 30, 828–834 (1986).
Neu, H. C., Novelli, A. & Chin, N. In vitro activity and β-lactamase stability of a new carbapenem, SM-7338. Antimicrob. Agents Chemother. 33, 1009–1018 (1989).
Alvarez-Lerma, F., Grau, S. & Ferrandez, O. Characteristics of doripenem: a new broad-spectrum antibiotic. Drug Des. Devel. Ther. 3, 173–190 (2009).
Park, S. W., We, J. S., Kim, G. W., Choi, S. H. & Park, H. S. Stability of new carbapenem DA-1131 to renal dipeptidase (dehydropeptidase I). Antimicrob. Agents Chemother. 46, 575–577 (2002).
Mori, M., Hikida, M., Nishihara, T., Nasu, T. & Mitsuhashi, S. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I. J. Antimicrob. Chemother. 37, 1034–1036 (1996).
Hikida, M., Kawashima, K., Yoshida, M. & Mitsuhashi, S. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J. Antimicrob. Chemother. 30, 129–134 (1992).
Fung-Tomc, J. C. et al. Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39, 394–399 (1995).
Fukuda, T. et al. In vitro and In vivo antibacterial activity of CS-834, a novel oral carbapenem. Antimicrob. Agents Chemother. 41, 2652–2663 (1997).
Kumagai, T., Tamai, S., Abe, T. & Hikida, M. Current status of oral carbapenem development. Curr. Med. Chem. Anti-Infective Agents 1, 1–14 (2002).
Kobayashi, R. et al. In vitro activity of tebipenem, a new oral carbapenem antibiotic, against Penicillin-nonsusceptible Streptococcus pneumoniae. Antimicrob. Agents Chemother. 49, 889–894 (2005).
Miyazaki, S. et al. In vitro and In vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections. Antimicrob. Agents Chemother. 45, 203–207 (2001).
Hikida, M., Itahashi, K., Igarashi, A., Shiba, T. & Kitamura, M. In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent Antipneumococcal Activity. Antimicrob. Agents Chemother. 43, 2010–2016 (1999).
Baldwin, C. M., Lyseng-Williamson, K. A. & Keam, S. J. Meropenem a review of its use in the treatment of serious bacterial infections. Drugs 68, 803–838 (2008).
Kasai, M. et al. AS-924, a novel bifunctional prodrug of ceftizoxime. J. Antibiot. 52, 491–500 (1999).
Kasai, M. et al. AS-924, a novel orally active bifunctional prodrug of ceftizoxime. Synthesis and relationship between physicochemical properties and oral absorption. Chem. Pharm. Bull. 47, 1081–1088 (1999).
Abrahamsson, K. et al. Pivalic acid-induced carnitine deficiency and physical exercise in humans. Metab. Clin. Exp. 45, 1501–1507 (1996).
Alexander, J., Cargill, R., Michelson, S. R. & Schwam, H. (Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes. J. Med. Chem. 31, 318–322 (1988).
Matsumura, H., Bando, T. & Sunagawa, M. An efficient synthesis of (2S,4S)-2-substituted-4-mercaptopyrrolidine derivatives. Heterocycles 41, 147–159 (1995).
Mori, M. & Oida, S. A short-step synthesis of orally active carbapenem antibiotic CS-834. Chem. Pharm. Bull. 48, 126–130 (2000).
Matsumoto, F. & Oizumi, K. Cefuroxime axetil. Jpn. J. Antibiot. 41, 1181–1193 (1988).
Totsuka, K. et al. Effects of food intake and age on the pharmacokinetics of AS-924, a novel ester-type cephem antibiotic. Comparison with cefpodoxime proxetil. Int. J. Antimicrob. Agents 18, 463–469 (2001).
Miyazaki, S. et al. Novel orally active prodrugs of meropenem, KL-3744 and KL-3758: prediction of their efficacy for causative pathogens of respiratory tract infections (RTIs). Abstract book of 43rd Annual Interscience Conference of Antimicrobial Agents and Chemotherapy, 231 (2003).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tanaka, S., Matsui, H., Kasai, M. et al. Novel prodrugs of meropenem with two lipophilic promoieties: synthesis and pharmacokinetics. J Antibiot 64, 233–242 (2011). https://doi.org/10.1038/ja.2010.164
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ja.2010.164
